Turk Bela R, Theda Christiane, Fatemi Ali, Moser Ann B
Hugo W Moser Research Institute, Kennedy Krieger Institute, Baltimore, MD, USA.
Neonatal Services, Royal Women's Hospital, Murdoch Children's Research Institute and University of Melbourne, Melbourne, VIC, Australia.
Int J Dev Neurosci. 2020 Feb;80(1):52-72. doi: 10.1002/jdn.10003. Epub 2020 Jan 26.
Adrenoleukodystrophy (ALD) is a rare X-linked disease caused by a mutation of the peroxisomal ABCD1 gene. This review summarizes our current understanding of the pathogenic cell- and tissue-specific roles of lipid species in the context of experimental therapeutic strategies and provides an overview of critical historical developments, therapeutic trials and the advent of newborn screening in the USA. In ALD, very long-chain fatty acid (VLCFA) chain length-dependent dysregulation of endoplasmic reticulum stress and mitochondrial radical generating systems inducing cell death pathways has been shown, providing the rationale for therapeutic moiety-specific VLCFA reduction and antioxidant strategies. The continuing increase in newborn screening programs and promising results from ongoing and recent therapeutic investigations provide hope for ALD.
肾上腺脑白质营养不良(ALD)是一种由过氧化物酶体ABCD1基因突变引起的罕见X连锁疾病。本综述总结了我们目前对脂质种类在实验性治疗策略背景下的致病细胞和组织特异性作用的理解,并概述了关键的历史发展、治疗试验以及美国新生儿筛查的出现。在ALD中,已显示内质网应激和线粒体自由基生成系统的超长链脂肪酸(VLCFA)链长度依赖性失调会诱导细胞死亡途径,这为治疗性部分特异性VLCFA降低和抗氧化策略提供了理论依据。新生儿筛查项目的持续增加以及正在进行和近期治疗研究的 promising 结果为ALD带来了希望。 (注:原文中“promising”拼写错误,正确拼写为“promising”,翻译为“有希望的” )